ATP13A3 Inhibitors
ATP13A3 inhibitors encompass a diverse group of chemical compounds that indirectly suppress the activity of ATP13A3 by modulating various ion gradients and signaling mechanisms within the cell. Cardiac glycosides such as ouabain and 12β-hydroxydigitoxin exert their inhibitory effects on ATP13A3 by targeting the Na+/K+-ATPase pump, leading to an increase in intracellular sodium levels and a consequent disruption of the sodium gradient that is essential for the optimal function of ATP13A3. Similarly, monensin neutralizes sodium levels across membranes, which further hinders ATP13A3 by eradicating the sodium gradient it depends on. Bafilomycin A1 and omeprazole, through their respective inhibition of V-ATPase and gastric proton pumps, also contribute to the diminished activity of ATP13A3 by altering proton gradients and pH levels. Thapsigargin, a SERCA pump inhibitor, raises cytosolic calcium levels that activate calcium-dependent phosphatases, potentially leading to dephosphorylation and reduced ATP13A3 activity. Vanadate, by inhibiting phosphatases, could alter the phosphorylation equilibrium, indirectly affecting ATP13A3's function.
Further modulation of ATP13A3's activity is achieved through the manipulation of ion channels and cellular membrane potentials. Amiloride and niflumic acid may disrupt the ion homeostasis and electrochemical gradients necessary for ATP13A3's action, leading to its decreased activity. Diazoxide's ability to open ATP-sensitive potassium channels results in hyperpolarization, which could affect ATP13A3's function. Linoleic Acid, a potassium channel blocker, also alters the membrane potential and potassium gradient, which may indirectly decrease ATP13A3's activity. Verapamil's role as a calcium channel blocker further illustrates the complexity of ion-dependent regulation of ATP13A3, as the reduction in intracellular calcium can influence the phosphorylation state and thereby the activity of ATP13A3. Collectively, these inhibitors orchestrate a multi-faceted decrease in ATP13A3's activity by perturbing the delicate balance of ion gradients and signaling pathways that ATP13A3 relies upon.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain is a cardiac glycoside that inhibits the Na+/K+-ATPase pump. By inhibiting this pump, intracellular sodium levels rise, which indirectly affects the sodium gradient dependent ATPases like ATP13A3, leading to a diminished functionality of ATP13A3 as it relies on the sodium gradient to transport its substrates. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
12β-Hydroxydigitoxin is another cardiac glycoside that specifically inhibits the Na+/K+-ATPase. Similar to ouabain, it increases intracellular sodium levels, which can indirectly inhibit ATP13A3 by collapsing the sodium gradient necessary for its activity, thus diminishing ATP13A3's ability to maintain ion homeostasis. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a sodium ionophore that disrupts sodium ion gradients across biological membranes. By equilibrating sodium levels, it can indirectly inhibit sodium-dependent ATPases like ATP13A3 by removing the gradient required for its transport function, thereby diminishing ATP13A3's activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to an increase in cytosolic calcium levels. Elevated cytosolic calcium can activate calcium-dependent phosphatases which can dephosphorylate and thereby diminish the activity of ATP13A3, as its function is regulated by its phosphorylation state. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that decreases intracellular calcium levels. By reducing calcium signaling, it could indirectly affect the phosphorylation state and thus the activity of ATP13A3, which may be regulated by calcium-dependent kinases or phosphatases, leading to diminished activity of ATP13A3. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a V-ATPase inhibitor that disrupts proton gradients across intracellular organelles. This disruption can lead to a cellular environment that indirectly affects ATP13A3's activity, as ATP13A3 may require specific proton gradients for optimal functionality, thus diminishing its activity. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Amiloride is a potassium-sparing diuretic that inhibits Na+/H+ exchangers. By inhibiting these exchangers, it can alter intracellular pH and sodium levels, which may indirectly inhibit ATP13A3 by disrupting the ion gradients and pH levels required for its activity, thus leading to a decrease in ATP13A3's functional activity. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole is a proton pump inhibitor that decreases gastric acid secretion. It can indirectly affect ATP13A3 by altering the proton gradient and pH, which is essential for ATP13A3's function, leading to diminished activity as ATP13A3 is potentially dependent on pH for its transport mechanism. | ||||||
Sodium metavanadate | 13718-26-8 | sc-251034 sc-251034A | 5 g 25 g | $32.00 $84.00 | 3 | |
Sodium metavanadate is a competitive inhibitor of phosphatase enzymes and can mimic phosphate in many biological reactions. By inhibiting phosphatases, it can lead to hyperphosphorylation of proteins, potentially affecting ATP13A3's activity if it is regulated by a balance of phosphorylation and dephosphorylation, thus indirectly leading to a decrease in its functional activity. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
Niflumic acid is an inhibitor of chloride channels. If ATP13A3 activity is coupled to chloride ion transport, the inhibition of these channels could disrupt the ion balance and indirectly diminish ATP13A3's functionality by disrupting the electrochemical gradient it relies on. | ||||||